Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CK Life Sciences Int'l., (Holdings) Inc.
長 江 生 命 科 技 集 團 有 限 公 司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 0775)

BUSINESS UPDATE ON DOGWOOD THERAPEUTICS, INC.

CK Life Sciences Int'l., (Holdings) Inc. (the "**Company**") wishes to provide an update regarding its investment in Dogwood Therapeutics, Inc. ("**Dogwood**"). Dogwood is a development-stage biopharmaceutical company focused on developing potential first-in-class, new non-opioid medicines to treat pain and neuropathic disorders. Dogwood is incorporated in Delaware and listed on the Nasdaq Capital Market under the ticker symbol DWTX. The Company currently holds an approximate 75.2% indirect shareholding interest in Dogwood.

On 23 November 2026, after Hong Kong trading hours, Dogwood announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2b trial evaluating Halneuron® administered subcutaneously in cancer survivors suffering from chemotherapy-induced neuropathic pain (**"CINP"**). The study met its prespecified primary endpoint, demonstrating a statistically significant increase in the proportion of patients achieving at least a 50% reduction from baseline in weekly average pain intensity at Week 4 as compared with placebo. The observed 50% pain reduction represents a treatment effect that is clinically meaningful in this difficult-to-treat condition for which there are no FDA-approved treatments. Notably, reduction in pain was observed when Halneuron® was used alone or when used on top of other approved chronic pain medications.

It should be noted that Halneuron® is still at the Phase 2b clinical trial stage for CINP and the data is subject to further review by the relevant regulatory authorities. There is accordingly no assurance of the outcome. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 23 November 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).